MOdification Of THe Early-Life Respiratory Microbiome Through Vaginal SEEDing (MOTHER SEED)

November 6, 2025 updated by: Christian Rosas-Salazar, Vanderbilt University Medical Center
This is a single-center, parallel-arm, blind, sham-controlled, feasibility randomized controlled trial (RCT) to be conducted in healthy cesarean-born children. Eligible children will be randomized 1:1 to have their nose swabbed with either maternal vaginal secretions or a sterile swab (intervention vs. control group, respectively). The main hypothesis is that conducting an RCT assessing the utility of vaginal seeding in modifying the early-life upper respiratory tract (URT) microbiome of children born by cesarean section (C-section) is feasible and that the intervention is safe.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Eligible children will be randomized 1:1 to have their nose swabbed with either maternal vaginal secretions or a sterile swab (intervention vs. control group, respectively). The procedure will be performed following birth by C-section and immediately after the initial newborn care by the general pediatric team. The mother and child will then receive usual medical care as determined by their health care providers. Follow-up will occur at multiple time points during the child's first 6 months of life. One planned interim analysis to assess the safety of the procedure will be conducted.

The intervention aims to transfer the maternal vaginal microbiome to the nasal cavity of cesarean-born children at birth (i.e., vaginal seeding of the URT). Hence, the intervention simply attempts to replicate the natural exposure to maternal vaginal secretions during vaginal delivery in children born by C-section.

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Tennessee
      • Nashville, Tennessee, United States, 37232
        • Recruiting
        • Vanderbilt University Medical Center
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

For the mother:

  • Female 18-40 years of age who is in good general health, is fully able to provide consent to participate in the study, anticipates being available for the duration of the study, and is willing to comply with all study procedures
  • Singleton pregnancy
  • Completed ≧3 prenatal care visits at Vanderbilt University Medical Center (any facility)
  • Having rectovaginal swabs collected at ≧36 weeks of gestation to screen for Group B Streptococcus (GBS) as part of prenatal screening tests
  • Having a scheduled (planned or non-emergency) C-section at Vanderbilt University Medical Center (main campus only)
  • No intent to relocate outside the middle Tennessee region within 12 months of recruitment

For the child:

  • Estimated gestational age ≧37 weeks
  • Birth weight ≧2,500 grams

Exclusion Criteria:

For the mother:

  • Past medical history of any of the following:

    • Previous child with GBS infection or prior positive GBS testing
    • Hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
    • Genital herpes simplex virus (HSV) infection, genital herpetic lesions, or prior positive genital HSV testing
    • Genital human papilloma virus (HPV) infection, genital HPV lesions, or prior positive genital HPV testing
    • Diabetes type I or type II
  • Laboratory evidence during the current pregnancy of any of the following:

    • GBS bacteriuria in urine samples collected at any time (performed as standard of care)
    • GBS colonization in rectovaginal swabs collected at ≧36 weeks of gestation (performed as standard of care)
    • Chlamydia, trichomoniasis, or gonorrhea in urine samples collected at ≧36 weeks of gestation (performed as part of the screening procedures for this study)
    • Hepatitis B, hepatitis C, HIV, or syphilis in blood samples collected at ≧36 weeks of gestation (performed as part of the screening procedures for this study)
  • Uncontrolled gestational diabetes
  • Any serious obstetric disease (e.g., preeclampsia with severe features, placental abruption or severe bleeding, or thromboembolic disease) as deemed by the PI or co-investigators
  • Prior abnormal Pap smear
  • C-section scheduled for a genitourinary infection that would have interfered with vaginal delivery (e.g., genital herpetic lesions)
  • Lack of available prenatal screening tests
  • Use of systemic (i.e., oral, intramuscular, or intravenous) antibiotics in the 4 weeks prior to delivery (except for those being administered as part of the C-section)
  • Use of systemic (i.e., oral, intramuscular, or intravenous) immunosuppressive, biologic, or chemotherapeutic agents in the 3 months prior to delivery (except for systemic immunosuppressive agents not being used for their immunosuppressive effects [e.g., prenatal intramuscular beclomethasone for fetal lung maturation])
  • Fever (≧100.4°F [38°C]) in the 72 hours prior to delivery
  • Symptoms (e.g., dysuria, pruritus, or discharge) suggestive of a genitourinary infection (e.g., bacterial vaginosis, vaginal yeast infection, chorioamnionitis, or urinary tract infection) on the day of delivery
  • Symptoms (e.g., pain, tenderness, tingling, burning, itching, or swollen lymph nodes) suggestive of genital HSV infection on the day of delivery
  • Other symptoms (e.g., new-onset rhinorrhea, sore throat, cough, body aches, chills, nausea, vomiting, or diarrhea) suggestive of an acute infectious disease on the day of delivery
  • Physical exam findings (e.g., fever [≧100.4°F (38°C)] or vesicles, warts, or ulcers in the genital, perineal, or anal region) suggestive of a genitourinary infection on the day of delivery (performed as part of the screening procedures for this study if not performed as standard of care)
  • Maternal vaginal pH>4.5 on the day of delivery (performed as part of the screening procedures for this study)
  • Need for a switch from a scheduled C-section to an emergency C-section
  • Prelabor prolonged rupture of membranes (i.e., ≧18 hours prior to delivery)
  • Pregnancy as the result of an assisted reproductive technology or surrogacy
  • Participation in another clinical trial that involves an intervention that could impact the quality or interpretation of the study data as deemed by the PI or co-investigators
  • Other past or current medical problems that could compromise the safety of participants, interfere with their ability to comply with study requirements, or impact the quality or interpretation of the study data as deemed by the PI or co-investigators

For the child:

  • Need for neonatal measures outside routine clinical care (i.e., drying, tactile stimulation, bulb syringe or catheter suction of nose and mouth, or temperature maintenance) in the delivery room
  • Transfer to the neonatal intensive care unit immediately after delivery
  • Thick particulate meconium noted during delivery
  • Physical exam findings (e.g., tachypnea, nasal flaring, retractions, cyanosis, or grunting) suggestive of neonatal acute respiratory distress immediately after delivery (performed as part of the screening procedures for this study)
  • Prenatal diagnosis of a serious genetic, respiratory, cardiovascular, or neurological disease
  • Prenatal diagnosis of intrauterine growth restriction
  • Prenatal diagnosis of a major congenital anomaly (e.g., cleft lip or palate, cystic hygroma, or giant omphalocele)
  • Participation in another clinical trial that involves an intervention that could impact the quality or interpretation of the study data as deemed by the PI or co-investigators
  • Other past or current medical problems that could compromise the safety of participants, interfere with their ability to comply with study requirements, or impact the quality or interpretation of the study data as deemed by the PI or co-investigators

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Intervention Group
Vaginal Seeding
Following birth by C-section and immediately after the initial newborn care by the general pediatric team, children randomized to the intervention group will have their nasal cavity swabbed with maternal vaginal secretions.
Sham Comparator: Control Group
Sterile Swab
Following birth by C-section and immediately after the initial newborn care by the general pediatric team, children randomized to the control group will have their nasal cavity swabbed with a sterile swab.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility of the RCT
Time Frame: Six months following randomization
The study will be considered "definitively feasible as proposed," "possibly feasible as proposed," or "not feasible as proposed" based on eligibility, consent, enrollment, and loss to follow-up rates, which could be used as preliminary data to inform the design of a future phase II RCT. For this study, "enrolled" will be defined as consented and screened, with eligibility verified, and the eligibility, consent, enrollment, and loss to follow-up rates will be calculated using the following formulas: 1) eligibility rate = number of participants who are eligible*100 / number of participants pre-screened, 2) consent rate = number of participants who provide consent*100 / number of participants who are eligible, 3) enrollment rate = number of participants who are enrolled*100 / number of participants consented and who complete screening procedures, and 4) loss to follow-up = number of participants who did not complete the end-of-study visit*100 rate / number of participants randomized.
Six months following randomization
Safety of the intervention
Time Frame: Six months following randomization
To be determined by the number of adverse events, serious adverse events, and unanticipated problems throughout the study, as defined using the standards set forth in the National Cancer Institute's - Common Terminology Criteria (NCI-CTCAE) for AEs version 4.0 and the United States Department of Health and Human Services - Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events: Office for Human Research Protections Guidance 2007
Six months following randomization

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Timing of the intervention
Time Frame: Immediately following administration of the intervention
The number of minutes after birth when the intervention is performed.
Immediately following administration of the intervention
Proportion of in-person study visits completed
Time Frame: Six months following randomization
The total number of in-person study visits completed by all participants*100 / total number of in-person visits expected for all participants for each study time point.
Six months following randomization
Common microbial ecology metrics of the maternal vaginal microbiome and of the early-life URT microbiome
Time Frame: At each study time point (birth, ~2 days, ~5 days, ~4 weeks, and ~6 months of age) and over time (longitudinally from birth to age 6 months)
The comparisons of the maternal vaginal microbiome on the day of delivery between study groups will be conducted using alpha-diversity (e.g., observed taxa, Shannon index, and Simpson indices), beta-diversity (e.g., Bray-Curtis, Jaccard, weighted UniFrac, and unweighted UniFrac indices), and differential abundance (at the amplicon sequence variant, genus, and/or family level) analyses. The early-life URT microbiome at each time point and over time will be compared between study groups using similar microbial ecology metrics. In pre-specified analyses, we will also compare the presence and abundance of the genus Lactobacillus and the predominant Lactobacillus amplicon sequence variants in the URT of children at each time point and over time between study groups, as this is the predominant taxa of the maternal vaginal microbiome during pregnancy.
At each study time point (birth, ~2 days, ~5 days, ~4 weeks, and ~6 months of age) and over time (longitudinally from birth to age 6 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Christian Rosas-Salazar, MD, MPH, Vanderbilt University Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 9, 2022

Primary Completion (Estimated)

August 10, 2028

Study Completion (Estimated)

August 10, 2028

Study Registration Dates

First Submitted

August 12, 2022

First Submitted That Met QC Criteria

August 15, 2022

First Posted (Actual)

August 17, 2022

Study Record Updates

Last Update Posted (Estimated)

November 10, 2025

Last Update Submitted That Met QC Criteria

November 6, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 220799
  • K23HL148638 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified next-generation sequencing data generated as part of this study will be deposited into NIH-sponsored or other scientific repositories immediately following a publication. Other de-identified individual participant data (IPD) that underlie the results reported in a manuscript will be shared with other parties upon request beginning 12 months and ending 36 months following a publication. In addition, the study protocol and informed consent documents will be uploaded to clinicaltrials.gov no later than 60 days after the end-of-study visit of the last enrolled participant.

IPD Sharing Time Frame

De-identified next-generation sequencing data generated as part of this study will be deposited into NIH-sponsored or other scientific repositories immediately following a publication. Other de-identified IPD that underlie the results reported in a manuscript will be shared with other parties upon request beginning 12 months and ending 36 months following a publication. In addition, the study protocol and informed consent documents will be uploaded to clinicaltrials.gov no later than 60 days after the end-of-study visit of the last enrolled participant.

IPD Sharing Access Criteria

Individual requests for de-identified IPD sharing from other parties will be evaluated and approved by the PI. For this, the requesting party will need to provide a methodologically sound proposal, obtain approval from their Institutional Review Board, and sing a data sharing agreement. De-identified IPD will be mainly shared for the purpose of conducting a systematic review with meta-analysis, but other studies will be evaluated on a case-by-case basis.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.